Large Vivus Shareholder Seeks More Change

But even if FDA agrees, one of Vivus' largest shareholders is still pushing ahead with plans to remake the company's board of directors First Manhattan, owners of 8.8% of Vivus' shares, called modification of the Qsymia risk management plan, "necessary but not sufficient for Qsymia's success." The investment fund, which is run by David Gottesman, a ... (more)

http://www.thestreet.com/story/11892029/1/large-vivus-shareholder-seeks-more-change.html